Post by Onco'Zine - The International Oncology Network

In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Tim Blauwkamp, Ph.D., Chief Scientific Officer and co-founder of Karius. Karius, based in Redwood City, CA, has developed a non-invasive liquid biopsy, a blood test, called the Karius Test®. The test is based on next-generation sequencing of microbial cell-free DNA and can rapidly detect pathogens causing serious infections, including those diseases that are difficult to diagnose through conventional methods. In the right patient population, the test is faster than conventional culture-based diagnostics and eliminates traditional diagnostic methods for deep-tissue infections, which may require a diagnostic surgical procedure. But overall, the test helps clinicians make rapid, treatment decisions. And this is especially important for infectious disease diagnostics in immunocompromised patients, including patients with cancer. Click on the link to listen to the program: https://lnkd.in/eeXY6Bn To support The Onco'Zine Brief visit: https://lnkd.in/egGRxZT To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. #cancertreatment #oncology #infection #hematology